Anti-Mouse ICOSL (HK5.3) In Vivo Antibody - Low Endotoxin

In stock
Only %1 left
SKU
ICH1229
Add to Compare
$400.00 - $2,945.00

Anti-Mouse ICOSL (HK5.3) In Vivo Antibody - Low Endotoxin

Endotoxin
≤ 1.0 EU/mg as determined by the LAL method
Purity
>95% by SDS-PAGE and HPLC
Species Reactivity
Mouse
Target
ICOSL
Concentration
≤ 2.0 mg/ml
Isotype
Rat IgG2a
Host
Rat
Aggregation
Aggregation level ≤ 5%
Immunogen
Transfected Cell Line for Mouse B7H2
Buffer
ICH3002-100ml
Uniprot
Q9JHJ8
Shipping Conditions
Blue ice
Background
ICOS ligand (ICOSL) engages ICOS on activated T cells to deliver co-stimulatory signals that shape T-cell differentiation, germinal-centre responses, and humoral immunity. Clone HK5.3 is a rat IgG2a monoclonal antibody recognising mouse ICOSL, validated for blocking, flow cytometry, neutralization, and in vivo applications. Anti-ICOSL HK5.3 is supplied in a low-endotoxin format suitable for in vivo use and manufactured in scalable milligram to gram quantities for bulk and high-throughput laboratories. As a research-use-only, non-therapeutic reagent, it delivers reproducible, lot-consistent performance for mouse co-stimulation, T-follicular-helper, and immune-regulation research programmes.
Other Names
ICOSLG, ICOS-L, B7RP-1, LICOS, B7 homolog 2, B7-H2, B7H2, B7h
Clone
HK5.3
Purification Method
This monoclonal antibody was purified using Protein G
Formulation
This antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2, 150 mM NaCl with no carrier protein, potassium or preservatives added.
Storage
This low endotoxin antibody is stable when stored at 2-8°C for at least four (4) weeks. For long-term storage aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Applications
Blocking, Flow Cytometry, in vivo, Neutralization
Use
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Write Your Own Review
You're reviewing:Anti-Mouse ICOSL (HK5.3) In Vivo Antibody - Low Endotoxin
Your Rating
Back to Top